Interactive Features

Quiz

Quiz: Treatment Regimen for Older Patients with Newly Diagnosed AML

10/13/2022

True or False: According to a recent phase 2 study, venetoclax added to cladribine and low-dose cytarabine alternating with venetoclax and 5-azacitidine was found to be an effective regimen for older or unfit patients with newly diagnosed AML.

True or False: According to a...

10/13/2022

Oncology

Quiz

Quiz: Post-Transplant Eprenetapopt and Azacitidine Maintenance in TP53-Mutant AML and MDS

10/05/2022

True or False: In a recent phase 2 trial, post-transplant eprenetapopt and azacitidine maintenance demonstrated promising safety and efficacy in TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

True or False: In a recent phase...

10/05/2022

Oncology

Quiz

Quiz: EFS Rates in Patients With IDH1-Mutated AML Treated With Ivosidenib and Azacitidine

09/13/2022

True or False: Treatment with ivosidenib and azacitidine was associated with improved event-free survival vs treatment with placebo and azacitidine in patients with newly diagnosed IDH1-mutated acute myeloid leukemia, according to a phase 3...

True or False: Treatment with...

09/13/2022

Oncology

Quiz

Quiz: Does Midostaurin Offer a Benefit for Patients With AML?

03/14/2022

True or false: Midostaurin has a significant benefit for patients with AML.

True or false: Midostaurin has a...

03/14/2022

Oncology

Test Your Knowledge

Quiz: Does Quizartinib Improve Survival in AML When Added to Nonintensive Chemo?

02/10/2022

True or false: A randomized trial found that quizartinib when added to standard nonintensive chemotherapy improves survival for older patients with AML.

True or false: A randomized...

02/10/2022

Oncology

Test Your Knowledge

Quiz: Does Quizartinib Improve Survival in AML When Added to Nonintensive Chemo?

02/10/2022

True or false: A randomized trial found that quizartinib when added to standard nonintensive chemotherapy improves survival for older patients with AML.

True or false: A randomized...

02/10/2022

Oncology

Test Your Knowledge

Quiz: Which Combo Regimen Improves ORR in Patients With Mutant-IDH2 AML?

01/31/2022

Question: Which of the following combination regimens was well tolerated and significantly improved ORR compared to monotherapy in patients with mutant-IDH2 AML?

Question: Which of the following...

01/31/2022

Oncology

Test Your Knowledge

Quiz: Which Combo Regimen Improves ORR in Patients With Mutant-IDH2 AML?

01/31/2022

Question: Which of the following combination regimens was well tolerated and significantly improved ORR compared to monotherapy in patients with mutant-IDH2 AML?

Question: Which of the following...

01/31/2022

Oncology

Quiz

Quiz: Is This Monotherapy Safe, Well-Tolerated in Newly Diagnosed AML?

01/20/2022

According to data from a phase 2b study, which of the following therapies is generally safe and effective as a first-line therapy for AML patients who are unfit for intensive chemotherapy?

According to data from a phase...

01/20/2022

Oncology

Quiz

Quiz: Is This Monotherapy Safe, Well-Tolerated in Newly Diagnosed AML?

01/20/2022

According to data from a phase 2b study, which of the following therapies is generally safe and effective as a first-line therapy for AML patients who are unfit for intensive chemotherapy?

According to data from a phase...

01/20/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology